44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Clinical Cardiology Journal

Sign up for email alert when new content gets added: Sign up

Oleksiy V. Goriachyi* and Anatoliy I. Gozhenko
Ukrainian Research Institute of Transport Medicine, Odessa Regional Clinical Hospital, Ukraine, Email: [email protected]
*Correspondence: Oleksiy V. Goriachyi, Ukrainian Research Institute of Transport Medicine, Odessa Regional Clinical Hospital, Odessa, Bocharova str.40 fl.31, 65111, Ukraine, Tel: +380505733030, Email: [email protected]

Received: 15-Jan-2019 Accepted Date: Feb 27, 2019; Published: 05-Mar-2019

Citation: Goriachyi OV, Gozhenko AI. Mmp-9 and the catheter ablation tactics choice. Clin Cardiol J 2019;3(1):9-15

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]


Objectives: The purpose of this study was to determine the relationship between matrix metalloproteinase 9 and atrial fibrillation recurrence after catheter ablation.

Background: Matrix metalloproteinase – 9 (MMP-9) is involved in extracellular matrix remodeling which is a marker of extracellular collagen degradation.

Methods: An enzyme-linked immunosorbent assay prior to a radiofrequency catheter ablation (RFA) procedure was used for measuring the serum level of MMP-9 in 210 patients: 80 patients without history of atrial fibrillation (AF) and 80 patients with idiopathic AF (paroxysmal AF – 30, persistent AF – 32, long-standing AF – 35 and permanent AF – 33). Their relationship with intraoperative efficacy and recurrence of AF was evaluated throughout the entire observation period.

Results: The observation period was 22.2 ± 7.9 months. MMP-9 level was higher in the groups of patients with AF than in the control group: 170.5 ± 24.2, 202.7±28.4, 230.8 ± 21.1 and 252.6 ± 24.5 ng/ml for paroxysmal, persistent, long-standing and permanent forms of AF. In the control group, MMP-9 level was 75.9 ± 14.6 ng/ml. MMP-9 level increased with the progression of AF (p <0.05). A multifactor analysis showed that MMP-9 level, history of atrial fibrillation and left atrial volume were independent predictors of sinus rhythm recovery and recurrence of AF.

Conclusion: An increase in MMP-9 level in patients with AF has been shown. An increase in MMP-9 levels was observed as AF progressed. MMP-9 is an independent predictor of arrhythmia recurrence after RFA.

Google Scholar citation report
Citations : 12

Clinical Cardiology Journal received 12 citations as per Google Scholar report